(19)
(11) EP 2 752 428 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
26.02.2020 Bulletin 2020/09

(45) Mention of the grant of the patent:
13.11.2019 Bulletin 2019/46

(21) Application number: 14162664.8

(22) Date of filing: 25.06.2009
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
A61K 39/395(2006.01)
C07K 16/22(2006.01)
C12N 15/13(2006.01)

(54)

Humanization of rabbit antibodies using a universal antibody framework

Humanisierung von Kaninchen-Antikörpern unter Verwendung eines universellen Antikörper-Frameworks

Humanisation d'anticorps de lapins au moyen d'une région charpente d'anticorps universelle


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: 25.06.2008 US 75697 P
25.06.2008 US 75692 P
24.02.2009 US 155041 P
24.02.2009 US 155105 P
02.06.2009 CH 8322009

(43) Date of publication of application:
09.07.2014 Bulletin 2014/28

(60) Divisional application:
19208570.2

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09768695.0 / 2307458

(73) Proprietor: NOVARTIS AG
4056 Basel (CH)

(72) Inventors:
  • Borras, Leonardo
    8952 Schlieren (CH)
  • Urech, David
    8645 Jona (CH)

(74) Representative: Grünecker Patent- und Rechtsanwälte PartG mbB 
Leopoldstraße 4
80802 München
80802 München (DE)


(56) References cited: : 
EP-A- 1 918 302
WO-A-2007/001851
WO-A-2007/124610
WO-A-2008/004834
WO-A2-01/30393
WO-A2-2005/035575
WO-A2-2007/042809
US-A1- 2005 033 031
US-A1- 2006 216 293
WO-A-2006/131013
WO-A-2007/047112
WO-A-2007/140371
WO-A-2008/006235
WO-A2-2004/016740
WO-A2-2007/042775
WO-A2-2008/118356
US-A1- 2005 048 578
   
  • HONEGGER A ET AL: "Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 309, no. 3, 8 June 2001 (2001-06-08), pages 657-670, XP004626893, ISSN: 0022-2836
  • EWERT S ET AL: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 34, no. 2, 1 October 2004 (2004-10-01), pages 184-199, XP004526805, ISSN: 1046-2023
  • EWERT S ET AL: "STRUCTURE-BASED IMPROVEMENT OF THE BIOPHYSICAL PROPERTIES OF IMMUNOGLOBULIN VH DOMAINS WITH A GENERALIZABLE APPROACH", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 42, no. 6, 18 February 2003 (2003-02-18), pages 1517-1528, XP008052212, ISSN: 0006-2960
  • KNAPPIK A ET AL: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 296, no. 1, 11 February 2000 (2000-02-11), pages 57-86, XP004461525, ISSN: 0022-2836
  • RADER C ET AL: "THE RABBIT ANTIBODY REPERTOIRE AS A NOVEL SOURCE FOR THE GENERATIONOF THERAPEUTIC HUMAN ANTIBODIES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 275, no. 18, 5 May 2000 (2000-05-05), pages 13668-13676, XP001023515, ISSN: 0021-9258, DOI: 10.1074/JBC.275.18.13668
  • POPKOV M ET AL: "Rabbit Immune Repertoires as Sources for Therapeutic Monoclonal Antibodies: The Impact of Kappa Allotype-correlated Variation in Cysteine Content on Antibody Libraries Selected by Phage Display", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 325, no. 2, 10 January 2003 (2003-01-10), pages 325-335, XP004457536, ISSN: 0022-2836
  • JUNG S ET AL: "IMPROVING IN VIVO FOLDING AND STABILITY OF A SINGLE-CHAIN FV ANTIBODY FRAGMENT BY LOOP GRAFTING", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 8, 1 January 1997 (1997-01-01), pages 959-966, XP000971779, ISSN: 0269-2139
  • ROCHA R ET AL: "Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry", PATHOLOGY RESEARCH AND PRACTICE, GUSTAV FISCHER, STUTTGART, DE, vol. 204, no. 9, September 2008 (2008-09), pages 655-662, XP024098831, ISSN: 0344-0338 [retrieved on 2008-06-18]
  • OTTIGER MICHAEL ET AL: "Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 50, no. 2, 1 February 2009 (2009-02-01), pages 779-786, XP009116265, ISSN: 0146-0404
  • FURRER ESTHER ET AL: "Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 50, no. 2, 1 February 2009 (2009-02-01), pages 771-778, XP009116264, ISSN: 0146-0404 [retrieved on 2008-08-29]
  • KÜGLER MARKUS ET AL: "Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS MAR 2009, vol. 22, no. 3, March 2009 (2009-03), pages 135-147, XP002575212, ISSN: 1741-0134
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).